Reversion of erlotinib-acquired resistance twice by chemotherapy

References

• Moran T, Sequist LV. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J ClinOncol 2012; 30:3330 - 6; http://dx.doi.org/10.1200/JCO.2012.43.1858; PMID: 22753908
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947 - 57; http://dx.doi.org/10.1056/NEJMoa0810699; PMID: 19692680
   PubMed Web of Science ®Google Scholar
• Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73; http://dx.doi.org/10.1371/journal.pmed.0020073; PMID: 15737014
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528 - 38; http://dx.doi.org/10.1016/S1470-2045(12)70087-6; PMID: 22452896
   PubMed Web of Science ®Google Scholar
• Brugger W, Thomas M. EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment. Lung Cancer 2012; 77:2 - 8; http://dx.doi.org/10.1016/j.lungcan.2011.12.014; PMID: 22281074
   PubMed Web of Science ®Google Scholar
• Oxnard GR. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer. Arch Pathol Lab Med 2012; 136:1205 - 9; http://dx.doi.org/10.5858/arpa.2012-0254-RA; PMID: 23020725
   PubMed Web of Science ®Google Scholar
• Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Jänne PA, Johnson BE, Van den Abbeele AD. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 2010; 195:W221-8; http://dx.doi.org/10.2214/AJR.09.3928; PMID: 20729419
   PubMedGoogle Scholar
• Oh IJ, Ban HJ, Kim KS, Kim YC. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 2012; 77:121 - 7; http://dx.doi.org/10.1016/j.lungcan.2012.01.012; PMID: 22333554
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. SciTransl Med 2011; 3:90ra59; http://dx.doi.org/10.1126/scitranslmed.3002356; PMID: 21734175
   PubMed Web of Science ®Google Scholar
• Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011; 17:6298 - 303; http://dx.doi.org/10.1158/1078-0432.CCR-11-1468; PMID: 21856766
   PubMed Web of Science ®Google Scholar
• Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, Kris MG, Tran HT, Klein P, Li X, et al, TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J ClinOncol 2005; 23:5892 - 9; http://dx.doi.org/10.1200/JCO.2005.02.840; PMID: 16043829
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Janjigian YY, Arcila ME, Sima CS, Kass SL, Riely GJ, Pao W, Kris MG, Ladanyi M, Azzoli CG, et al. Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib. Clin Cancer Res 2011; 17:6322 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-11-1080; PMID: 21831955
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. SciTransl Med 2011; 3:75ra26; http://dx.doi.org/10.1126/scitranslmed.3002003; PMID: 21430269
   PubMed Web of Science ®Google Scholar
• Ercan D, Zejnullahu K, Yonesaka K, Xiao Y, Capelletti M, Rogers A, Lifshits E, Brown A, Lee C, Christensen JG, et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene 2010; 29:2346 - 56; http://dx.doi.org/10.1038/onc.2009.526; PMID: 20118985
   PubMed Web of Science ®Google Scholar
• Nakata A, Gotoh N. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert OpinTher Targets 2012; 16:771 - 81; http://dx.doi.org/10.1517/14728222.2012.697155; PMID: 22762482
   PubMed Web of Science ®Google Scholar
• Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, et al. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci 2012; 103:1946 - 54; http://dx.doi.org/10.1111/j.1349-7006.2012.02408.x; PMID: 22863020
   PubMed Web of Science ®Google Scholar
• Kagawa S, Takano S, Yoshitomi H, Kimura F, Satoh M, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Furukawa K, et al. Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells. J Surg Res 2012; 178:758 - 67; http://dx.doi.org/10.1016/j.jss.2012.05.065; PMID: 22726648
   PubMed Web of Science ®Google Scholar